
Hengrui Pharma And GSK Enter Agreements To Develop Up To 12 Innovative Medicines Across Respiratory, Immunology & ...
(MENAFN- PR Newswire) Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK following phase I completion …